PEPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
PepGen Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.70+0.10 (+3.85%)
Close on Oct 19, 2026
- Market cap
- $186.85M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.2%
52M of 69M shares
Institutional holders
72
7 new, 27 sold out
Net institutional buying
-5M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $59.31K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Oxford Science Enterprises plc | 4,955,388 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Michael Kramarz | 4,475,000 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| Commodore Capital Master LP | 3,544,101 | 5.10% | 13G (passive) | Mar 4, 2026 |
| Viking Global Opportunities GP LLC | 3,482,434 | 5.03% | 13G (passive) amendment | Mar 31, 2026 |
| Halvorsen Ole Andreas | 3,482,434 | 5.10% | 13G (passive) | Sep 26, 2025 |
| RTW Investments, LP | 3,193,097 | 9.80% | 13G (passive) | Dec 31, 2024 |
| RA Capital Management, L.P. | 20,099,753 | 29.20% | 13D (active) amendment | Sep 26, 2025 |
| Suvretta Capital Management, LLC | 1,660,932 | 5.10% | 13G (passive) | Feb 5, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PEPG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 20,064,545 | 28.97% | $36.12M | – | 0.31% |
| Commodore Capital LP | 4,475,000 | 6.46% | $8.06M | – | 0.48% |
| Viking Global Investors LP | 3,482,434 | 5.03% | $6.27M | – | 0.02% |
| Laurion Capital Management LP | 2,750,855 | 3.97% | $4.95M | – | 0.13% |
| ADAR1 Capital Management, LLC | 2,591,085 | 3.74% | $4.66M | +983,447 | 0.21% |
| Vivo Capital, LLC | 2,325,000 | 3.36% | $4.19M | – | 0.38% |
| Vanguard Capital Management LLC | 1,935,920 | 2.80% | $3.48M | −1,779 | 0.00% |
| Millennium Management LLC | 1,786,765 | 2.58% | $3.22M | −292,378 | 0.00% |
| Renaissance Technologies LLC | 1,520,246 | 2.19% | $2.74M | +1,463,446 | 0.00% |
| BlackRock, Inc. | 1,304,262 | 1.88% | $2.35M | +26,478 | 0.00% |
| Marshall Wace, Llp | 866,992 | 1.25% | $1.56M | +568,424 | 0.00% |
| Gsa Capital Partners Llp | 852,852 | 1.23% | $1.54K | +814,566 | 0.10% |
| Citadel Advisors LLC | 658,381 | 0.95% | $1.19M | +450,459 | 0.00% |
| AWM Investment Company, Inc. | 600,000 | 0.87% | $1.08M | −1,230,925 | 0.09% |
| Monimus Capital Management, LP | 587,688 | 0.85% | $1.06M | −10,975 | 0.24% |
| Squarepoint Ops LLC | 529,083 | 0.76% | $952.35K | +382,487 | 0.00% |
| Geode Capital Management, LLC | 523,473 | 0.76% | $942.81K | −12,526 | 0.00% |
| Creek Drive Management Group LLC | 450,000 | 0.65% | $810.00K | – | 0.39% |
| Ikarian Capital, LLC | 447,165 | 0.65% | $804.90K | – | 0.09% |
| Diadema Partners LP | 373,284 | 0.54% | $671.91K | +222,359 | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 52M | 75.2% | 7 / 21 | 26 / 27 | 6M | 10M |
| Q1 2026 | 93 | 57M | 81.7% | 27 / 27 | 27 / 20 | 13M | 12M |
| Q4 2025 | 87 | 57M | 83.0% | 29 / 29 | 16 / 12 | 10M | 9M |
| Q3 2025 | 72 | 57M | 82.0% | 32 / 19 | 19 / 12 | 37M | 3M |
| Q2 2025 | 52 | 23M | 33.5% | 5 / 17 | 20 / 25 | 1M | 3M |
| Q1 2025 | 72 | 25M | 36.6% | 23 / 17 | 18 / 11 | 6M | 6M |
| Q4 2024 | 61 | 25M | 36.1% | 12 / 19 | 14 / 13 | 4M | 5M |
| Q3 2024 | 62 | 25M | 36.6% | 14 / 19 | 14 / 12 | 4M | 3M |
| Q2 2024 | 61 | 25M | 36.3% | 13 / 24 | 14 / 8 | 2M | 1M |
| Q1 2024 | 56 | 25M | 35.7% | 17 / 20 | 12 / 3 | 9M | 1M |
| Q4 2023 | 42 | 16M | 23.5% | 4 / 14 | 14 / 5 | 2M | 2M |
| Q3 2023 | 43 | 17M | 24.0% | 5 / 10 | 14 / 6 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PEPG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,408,449 | 2.03% | $2.54M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 480,909 | 0.69% | $865.64K | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 448,519 | 0.65% | $807.33K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 230,248 | 0.33% | $345.37K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 140,776 | 0.20% | $253.40K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 86,249 | 0.12% | $129.37K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 86,000 | 0.12% | $154.80K | 0.10% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 69,170 | 0.10% | $103.76K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 42,675 | 0.06% | $64.01K | 0.00% | May 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 42,601 | 0.06% | $63.90K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 26,673 | 0.04% | $48.01K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 19,889 | 0.03% | $35.80K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 9,517 | 0.01% | $17.13K | 0.01% | Jun 30, 2026 |
| JNL/DFA U.S. Small Cap Fund | 5,789 | 0.01% | $10.42K | 0.00% | Jun 30, 2026 |
| Invesco Nasdaq Biotechnology ETF | 3,627 | 0.01% | $5.44K | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James G. McArthur | President and CEO, Director | 296,457 | 0.43% | Mar 6, 2026 |
| Kasra Kasraian | Chief Technical Officer | 50,074 | 0.07% | May 26, 2026 |
| Noel Donnelly | Chief Financial Officer | 111,603 | 0.16% | Mar 6, 2026 |
| Paul Streck | EVP, Head of R&D | 76,226 | 0.11% | Mar 6, 2026 |
| Joseph Vittiglio | Chief Business & Legal Officer | 65,717 | 0.09% | Mar 2, 2026 |
| Mary Beth DeLena | General Counsel | 14,968 | 0.02% | Mar 5, 2025 |
| Laurie Keating | Director | 4,166 | 0.01% | Jun 22, 2026 |
| Joshua Resnick | Director | – | – | Jun 22, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 18,554,273 | 26.79% | Jun 22, 2026 |
| Howard Mayer | Director | – | – | Jun 22, 2026 |
| Lisa Wyman | Director | – | – | Jun 22, 2026 |
| Mitchell H. Finer | Director | – | – | Jun 22, 2026 |
| Habib J. Dable | Director | – | – | Jun 22, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 22, 2026 |
| Peter Kolchinsky | Director, 10% owner | 9,179,273 | 13.25% | Jun 22, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Jun 22, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | – | – | Jun 22, 2026 |
| Heidi Henson | Director | – | – | Jun 22, 2026 |
| Science Enterprises plc Oxford | – | 4,955,388 | 7.15% | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kasra Kasraian Chief Technical Officer | May 21, 2026 | Sale(10b5-1 plan) | −1,233 | $1.41 | $1.74K | 50,074 |
| Noel Donnelly Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −52 | $6.33 | $329 | 111,603 |
| Noel Donnelly Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −2,032 | $6.23 | $12.66K | 111,655 |
| James G. McArthur President and CEO, Director | Mar 4, 2026 | Sale(10b5-1 plan) | −5,144 | $6.23 | $32.05K | 296,457 |
| James G. McArthur President and CEO, Director | Mar 4, 2026 | Sale(10b5-1 plan) | −131 | $6.33 | $829 | 296,326 |
| Paul Streck EVP, Head of R&D | Mar 4, 2026 | Sale(10b5-1 plan) | −47 | $6.29 | $296 | 76,226 |
| Paul Streck EVP, Head of R&D | Mar 4, 2026 | Sale(10b5-1 plan) | −1,832 | $6.23 | $11.41K | 76,273 |
| Noel Donnelly Chief Financial Officer | Mar 1, 2026 | Award | +76,793 | – | – | 113,687 |
| James G. McArthur President and CEO, Director | Mar 1, 2026 | Award | +187,688 | – | – | 301,601 |
| Paul Streck EVP, Head of R&D | Mar 1, 2026 | Award | +50,300 | – | – | 78,105 |
| Joseph Vittiglio Chief Business & Legal Officer | Mar 1, 2026 | Award | +30,717 | – | – | 65,717 |
| Kasra Kasraian Chief Technical Officer | Mar 1, 2026 | Award | +34,557 | – | – | 51,307 |
| Joseph Vittiglio Chief Business & Legal Officer | Dec 8, 2025 | Award | +35,000 | – | – | 35,000 |
| Science Enterprises plc Oxford – | Sep 30, 2025 | Buy | +200,000 | $3.20 | $640.00K | 4,955,388 |
| Capital Healthcare Fund LP RA Director, 10% owner | Sep 26, 2025 | Buy | +9,375,000 | $3.20 | $30.00M | 18,554,273 |
| Paul Streck EVP, Head of R&D | May 30, 2025 | Buy | +8,375 | $1.24 | $10.39K | 27,805 |
| Kasra Kasraian Chief Technical Officer | May 20, 2025 | Award | +16,750 | – | – | 16,750 |
| James G. McArthur President and CEO, Director | Apr 17, 2025 | Buy | +10,000 | $1.36 | $13.60K | 113,913 |
| James G. McArthur President and CEO, Director | Apr 8, 2025 | Buy | +41,500 | $1.15 | $47.72K | 103,913 |
| Noel Donnelly Chief Financial Officer | Mar 3, 2025 | Award | +23,283 | – | – | 24,956 |
| Mary Beth DeLena General Counsel | Mar 3, 2025 | Award | +13,400 | – | – | 14,968 |
| Paul Streck EVP, Head of R&D | Mar 3, 2025 | Award | +19,430 | – | – | 19,430 |
| James G. McArthur President and CEO, Director | Mar 3, 2025 | Award | +60,719 | – | – | 62,413 |
| Noel Donnelly Chief Financial Officer | Feb 26, 2025 | Sale(10b5-1 plan) | −1,527 | $1.68 | $2.57K | 1,673 |
| Mary Beth DeLena General Counsel | Feb 26, 2025 | Sale(10b5-1 plan) | −1,432 | $1.68 | $2.41K | 1,568 |
| Noel Donnelly Chief Financial Officer | Feb 24, 2025 | Award | +3,200 | – | – | 3,200 |
| Mary Beth DeLena General Counsel | Feb 24, 2025 | Award | +3,000 | – | – | 3,000 |
| Michelle L. Mellion Chief Medical Officer | Jul 25, 2024 | Sale(10b5-1 plan) | −7,571 | $18.06 | $136.73K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 25, 2024 | Option exercise | +7,571 | $10.21 | $77.30K | 7,571 |
| Michelle L. Mellion Chief Medical Officer | Jul 24, 2024 | Sale(10b5-1 plan) | −201 | $18.01 | $3.62K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 24, 2024 | Option exercise | +201 | $10.21 | $2.05K | 201 |
| Michelle L. Mellion Chief Medical Officer | Jul 18, 2024 | Option exercise | +12,625 | $10.21 | $128.90K | 12,625 |
| Michelle L. Mellion Chief Medical Officer | Jul 18, 2024 | Sale(10b5-1 plan) | −12,625 | $18.20 | $229.78K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 16, 2024 | Sale(10b5-1 plan) | −5,901 | $18.00 | $106.22K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 16, 2024 | Option exercise | +5,901 | $10.21 | $60.25K | 5,901 |
| Michelle L. Mellion Chief Medical Officer | Jul 12, 2024 | Sale(10b5-1 plan) | −3,288 | $18.04 | $59.32K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 12, 2024 | Option exercise | +3,288 | $10.21 | $33.57K | 3,288 |
| Michelle L. Mellion Chief Medical Officer | Jul 2, 2024 | Option exercise | +37 | $10.21 | $378 | 37 |
| Michelle L. Mellion Chief Medical Officer | Jul 2, 2024 | Sale(10b5-1 plan) | −37 | $18.07 | $669 | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 1, 2024 | Option exercise | +875 | $10.21 | $8.93K | 875 |
| Michelle L. Mellion Chief Medical Officer | Jul 1, 2024 | Sale(10b5-1 plan) | −875 | $18.01 | $15.76K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jun 24, 2024 | Option exercise | +9,260 | $10.21 | $94.54K | 9,260 |
| Michelle L. Mellion Chief Medical Officer | Jun 24, 2024 | Sale(10b5-1 plan) | −9,260 | $18.19 | $168.44K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jun 12, 2024 | Option exercise | +1,086 | $10.21 | $11.09K | 1,086 |
| Michelle L. Mellion Chief Medical Officer | Jun 12, 2024 | Sale(10b5-1 plan) | −1,086 | $18.06 | $19.61K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jun 11, 2024 | Option exercise | +500 | $10.21 | $5.11K | 500 |
| Michelle L. Mellion Chief Medical Officer | Jun 11, 2024 | Sale(10b5-1 plan) | −500 | $18.04 | $9.02K | 0 |
| Michelle L. Mellion SVP, Clinical Development | Jun 6, 2024 | Sale(10b5-1 plan) | −1,411 | $18.00 | $25.40K | 0 |
| Michelle L. Mellion SVP, Clinical Development | Jun 6, 2024 | Option exercise | +1,411 | $10.21 | $14.41K | 1,411 |
| Michelle L. Mellion SVP, Clinical Development | Jun 5, 2024 | Option exercise | +7,245 | $10.21 | $73.97K | 7,245 |
| Michelle L. Mellion SVP, Clinical Development | Jun 5, 2024 | Sale(10b5-1 plan) | −7,245 | $18.09 | $131.06K | 0 |
| Niels Svenstrup SVP, Chem. Mfg & Controls | May 17, 2024 | Sale(10b5-1 plan) | −10,000 | $13.41 | $134.10K | 0 |
| Peter Kolchinsky Director, 10% owner | Feb 9, 2024 | Buy | +2,557,593 | $10.64 | $27.21M | 9,179,273 |
| James G. McArthur President and CEO, Director | Nov 30, 2023 | Buy | +1,694 | $4.17 | $7.06K | 1,694 |
| James G. McArthur President and CEO, Director | Jun 8, 2023 | Sale(10b5-1 plan) | −2,381 | $16.04 | $38.19K | 0 |
| James G. McArthur President and CEO, Director | Jun 8, 2023 | Option exercise | +2,381 | $2.71 | $6.45K | 2,381 |
| James G. McArthur President and CEO, Director | Jun 7, 2023 | Sale(10b5-1 plan) | −8,419 | $16.23 | $136.64K | 0 |
| James G. McArthur President and CEO, Director | Jun 7, 2023 | Option exercise | +8,419 | $2.71 | $22.82K | 8,419 |
| James G. McArthur President and CEO, Director | Jun 6, 2023 | Sale(10b5-1 plan) | −18,150 | $16.18 | $293.67K | 0 |
| James G. McArthur President and CEO, Director | Jun 6, 2023 | Option exercise | +18,150 | $2.71 | $49.19K | 18,150 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| L. Mellion Michelle Officer | Jun 5, 2024 | 50,000 | $788.00K | Jun 5, 2024 | Exercise of Stock Options |
| Svenstrup Niels Officer | May 17, 2024 | 10,000 | $136.50K | May 17, 2024 | Previously Exercised Stock Options |
| Jaya Goyal Officer | Mar 12, 2024 | 116,187 | $2.06M | Mar 12, 2024 | STOCK OPTION EXERCISE |
| McArthur James Officer | Jun 2, 2023 | 31,250 | $460.94K | Jun 2, 2023 | Exercise of Stock Options |